KES-0001 / Kesios Therap, Imperial College London - LARVOL DELTA

Cancer-selective targeting of the NF-κB pathway via GADD45β/MKK7 inhibition: Results from the phase I trial of the first-in-class inhibitor, DTP3, in patients with relapsed or refractory multiple myeloma (ASH 2025) - "In summary, DTP3 exhibited a favourable PK, PD, safety, and initial efficacy profile upon intravenousadministration at doses up to 45 mg/kg. A VGPR was observed in the patient treated at 30 mg/kg, and thecumulative PD and initial efficacy signals suggest broad clinical activity. A Phase IIA dose-expansion studyis ongoing to further evaluate the safety and clinical activity of DTP3 in patients with relapsed orrefractory MM and DLBCL, alongside development of predictive biomarkers for patient stratification."

Clinical • P1 data • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Hypotension • Lymphoma • Multiple Myeloma • Non-Hodgkin’s Lymphoma • Oncology • SDC1